patients, supported with a cf-LVAD. This approach suggested a potential role of ACT during reverse remodeling in cf-LVAD, which was experimentally confirmed in individual patients by ELISA, quantitative-polymerase chain reaction, and protein localization.
MicroRNAs (miRs) are small, noncoding RNAs that bind mRNAs at their 3′-untranslated regions (UTRs), stimulating mRNA degradation or inhibiting protein translation. 9 Delineating the role of miRs in post-transcriptional gene regulation offers new insight into the mechanisms by which the heart adapts to mechanical support. Moreover, miRs can be important hallmarks for recovery or deterioration and can be used as a therapeutic target in HF. 10 Therefore, the post-transcriptional regulation of ACT by miRs was investigated.
This study revealed a potential role of ACT, and its posttranscriptional regulator miR-137, in the pathophysiology of HF and reverse remodeling during mechanical support.
Methods

Study Population
Eighteen patients were included with a nonischemic DCM supported with a cf-LVAD (Heart-Mate II, Thoratec, CA) as bridge to heart transplantation (HTx). Plasma was collected before and 1, 3, and 6 months after LVAD implantation. Control plasma was collected from 6 healthy individuals.
Of the 18 patients included, 15 underwent HTx. Myocardial tissue of each individual patient was collected at time of LVAD implantation (pre-LVAD) and from the explanted left ventricle (post-LVAD), outside the suture area of the inflow cannula. Control myocardial tissue was obtained from 3 donor hearts declined for HTx (because of noncardiac reasons) and from biopsies of 7 donor hearts during HTx surgery. All LVAD patients gave written informed consent for the use of their tissues for research purposes.
2-Dimensional Difference Gel Electrophoresis
With the use of fluorescent 2-dimensional difference gel electrophoresis (2D-DIGE), a comparative analysis was made of protein expression in tissue and plasma of DCM patients before and after cf-LVAD implantation. Paired premyocardial and postmyocardial tissue of 8 patients and 4 controls were analyzed. In addition, EDTA plasma of 8 DCM patients and 5 controls was used before implantation and 6 months after implantation (online-only Data Supplement). Differentially expressed proteins were excised and identified by tandem mass spectrometry (online-only Data Supplement).
Plasma Levels of ACT
EDTA blood was centrifuged at 3000 rpm for 10 minutes, plasma was collected and stored at −20°C. Circulating ACT was determined by ELISA (online-only Data Supplement).
ACT mRNA and miR-137 Levels
Total RNA was isolated from 20 sections of 10-µm snap-frozen myocardial tissue using miRNeasy Mini Kit (Qiagen Inc, Austin, TX). Copy DNA for ACT was synthesized with superscript III, oligo-dT, and random primers (Life Technologies, Bleiswijk, The Netherlands). mRNA expression of ACT was determined by quantitative-polymerase chain reaction on the LightCycler-480 (Roche Diagnostics BV, Almere, The Netherlands), as described previously. 11 A detailed description is provided in the online-only Data Supplement. For miR-137, a 2-step protocol consisting of reverse transcription with an miR-specific primer followed by quantitative-polymerase chain reaction with a TaqMan probe was performed on the ViiA 7 (Life Technologies).
Immunohistochemistry
The expression of ACT and its major target for proteinase inhibition, cathepsin G (CG), was analyzed by immunohistochemistry in formalinfixed paraffin-embedded sections. Endogenous peroxidase was blocked with H 2 O 2 for 15 minutes. Sections were pretreated with either citrate (ACT) or EDTA (CG) and incubated with primary antibody diluted in PBS/1% BSA for 1 hour. (ACT, diluted 1:50, rabbit anti-human ACT, Dako, Glostrup, Denmark; CG diluted 1:100, mouse anti-human CG, Abcam, Cambridge, MA). Power Vision poly-Anti-Rabbit IgG (Immunovision Technologies, Hillsborough, FL) and RamPo (diluted 1:500+10% NHuS [normal human serum], polyclonal rabbit anti-mouse Immunoglobulin HRP [horseradish peroxidase], Dako) were used as secondary antibodies for ACT and CG, respectively. The slides were developed with DAB (3,3′-diaminobenzidine-hydrochloride) solution for 10 minutes. The nuclei were counterstained with Mayer's Haematoxylin. In every section, 3 areas were selected at random and the ACT staining of cardiomyocytes, epithelial and stromal cells was scored and the modus was calculated. ACT expression was analyzed using a scoring system; 0=no staining, 1=weak, 2=moderate, and 3=strong. This was performed individually by 3 observers, from which the intraobserver agreement was assessed using unweighted and weighted kappas.
Double-staining ACT and Anticardiac Actin
After staining with the primary antibody for ACT (diluted 1:50, rabbit anti-human ACT, Dako), slides were incubated with swine anti-rabbit Ig TRITC (tetramethylrhodamine isothiocyanate)-labeled (Dako, 1:40) in PBS and 10% AB serum. After a wash in PBS/Tween-20, the slides were incubated with a solution of PBS and 10% normal rabbit serum for 30 minutes. After decanting the solution, the slides were horizontally incubated with monoclonal antiactin (α-sarcomeric) antibody produced in mouse (Sigma-Aldrich Inc, St. Louis, CA, 1:500) in PBS and 10% normal rabbit serum. Incubation was followed by a washing step in PBS/Tween-20. The slides were horizontally incubated with rabbit anti-mouse fluorescein isothiocyanate (Dako, 1:50) in PBS and 10% AB-serum. After a wash with PBS/Tween-20, the slides were incubated with Topro-3 iodide (Life Technologies, 1:500) in PBS Tween-20 and coverslips were mounted onto object glasses using vectashieldmounting medium (VectorLaboratories Inc, Burlingame, CA).
In Situ Hybridization for ACT mRNA and miR-137
In situ hybridization (ISH) for ACT mRNA was performed on tissue slides from freshly frozen paired myocardial samples of 4 patients preand post-LVAD support and of 2 controls (donor hearts declined for HTx; online-only Data Supplement). Negative (ISH without probe) and positive controls were included. To test the specificity of the ISH signal of ACT, a nonrelevant probe (interleukin-2) was tested in parallel.
Locked nucleic acid (LNA) hybridization probes for miR-137 and negative control miRCURY LNA Sense (scramble) were conjugated with 3′-5′digoxigenin. Positive control probe U6 was conjugated with 5′digoxigenin. miR in situ was performed as described at http://www.exiqon.com/insitu. All LNA reagents were obtained from Exiqon (Vedbaek, Denmark).
miR Transfection
The human hepatoma cell line (HepG2) was used as a model to examine expression of ACT mRNA after miR-137 transfection. Cells were resuspended in normal growth medium to 1×10 5 cells/500 mL. A total of 0.5 μL of interleukin-6 was added to stimulate ACT production. Pre-miR miRNA Precursor Molecules for miR-137 (PM10513) or a Negative Precursor Control (AM17110; nontargeting sequence) were transfected with 1 μL lipofectamine RNAiMax, according to the instruction of the manufacturer (Life Technologies). In addition, some cells were left untreated (nontransfection). As a positive control for HepG2 transfection, miRNA Precursor molecules for miR-1 (PM10617) were transfected and the effect on protein tyrosine kinase-9, a validated miR-1 target, was determined. After 48 hours, total RNA of the HepG2 cells was isolated as described earlier.
The transfection experiments were performed 7× and 10× for miR-1 and mir-137, respectively.
Luciferase Assay
The 3′UTR of ACT was cloned into the pMIR-REPORT Luciferase vector (Life Technologies). Mutations for the miR-137 target site were generated by QuikChange II Site-Directed Mutagenesis (Agilent Technologies, Amstelveen, The Netherlands). To determine the suppression efficiency of miR-137, 4 luciferase experiments were performed. In each experiment 2×10 5 HEK293 (human embryonic kidney 293) cells were cotransfected with 200 ng pMIR-REPORT-ACT-3′UTR Luciferase vector, or the mutated vector and a pMIR-REPORT β-gal control plasmid for normalization of transfection efficiency. In addition, 50 nmol/L precursor miR-137, or a negative control precursor miR, or an miR without predicted target sites for ACT were introduced by using Lipofectamine 2000 (Life Technologies). Luciferase and β-galactosidase activity was assessed after 48 hours with the Luciferase Assay System and β-galactosidase Enzyme Assay System (Promega), respectively, as described before. 12
Statistical Analysis
Because of the small sample size and expected non-normality, the ACT isoforms and quantitative-polymerase chain reaction data (for ACT and miR-137) were presented as median with first and third quartile (Q1-Q3), and evaluated with the Wilcoxon signed-rank test. Plasma data were plotted and evaluated using the mixed-model analysis with a random intercept to account for the dependency between repeated measurements within the same patient. Data from patients pre-and post-LVAD were compared with those of healthy controls, using Mann-Whitney U test. The interobserver variability of ACT expression in the heart was indicated by unweighted and weighted kappas. The statistical analysis of 2D-DIGE gel spot volume quantification, transfection experiments, and the luciferase reporter assays were presented as mean and SEM and evaluated with the paired samples t test. A P≤0.05 was considered significant. All analyses were performed using SPSS, version 18 (SPSS, Inc, Chicago, IL).
Results
Patient Characteristics
Patient demographics are shown in the Table. All patients presented initially with HF New York Heart Association class IV despite optimal medical therapy, including intravenous inotropic therapy. Median age was 43 years (Q1-Q3, 28-48), 78% (n=14) was male and 44% (n=8) had a familial cause of DCM. A total of 61% (n=11) of the patients had a cardiac resynchronization therapy defibrillator or implantable cardioverter defibrillator before cf-LVAD implantation. The median duration of mechanical support, based on the patients who already underwent HTx (n=15), was 282 days (Q1-Q3, 207-521).
2D-DIGE Identifies ACT Changes in Plasma and Myocardial Tissue During LVAD Support
2D-DIGE on myocardial tissue of 8 DCM patients identified 40 proteins that changed significantly during cf-LVAD support, of which 9 were upregulated. 2D-DIGE on plasma of 8 DCM patients identified 97 proteins that were significantly different in the pre-pool versus the postpool. Ninety proteins were downregulated and 7 were upregulated. Of all proteins, only ACT changed significantly in both tissue and plasma during cf-LVAD support. Five different isoforms of ACT were detected in myocardial tissue, of which 2 were significantly downregulated during cf-LVAD support (1.78-2.39 downfold; Figure 1A -1F). Four different isoforms of circulating ACT were detected, all of them being significantly downregulated during cf-LVAD (2.03-2.74 downfold; Figure 1G -1J).
Elevated Circulating ACT Levels Normalize During Mechanical Support
ACT plasma levels were significantly elevated in end-stage HF patients before LVAD implantation as compared with levels in healthy controls (P=0.001; Figure 2A ). After 1 month of LVAD support, the concentration of circulating ACT showed a nonsignificant increase (P=0.08). However, after 3 and 6 months of LVAD support, plasma ACT decreased significantly compared with baseline (both P<0.001) and ultimately reached a similar level as of controls (P=0.18).
ACT mRNA and Protein Expression Change During Mechanical Support
Myocardial mRNA expression of ACT was increased in DCM patients before cf-LVAD implantation in comparison with controls, but did not reach significance (P=0.26; Figure 2B ). After cf-LVAD support, mRNA ACT decreased significantly (median change, −0.41, Q1−Q3, −1.71 to −0.17; P=0.004) to levels lower than that of controls (P=0.01).
Localization and distribution of ACT protein in the myocardium during cf-LVAD support was determined by immunohistochemistry. ACT-expression before LVAD support was weak to moderate in the cardiomyocytes, whereas the expression of ACT in the endothelium and stromal cells in the interstitium was strong (arrowheads; Figure 3A ). If present, †Familial DCM is defined if the patient has one or more family members diagnosed with idiopathic DCM or has a first-degree relative with an unexplained sudden death under the age of 35 y.
‡Days of LVAD support are based on the patients who already underwent heart transplantation (n=15).
inflammatory cells tended to stain as well. After LVAD support ( Figure 3B ), ACT expression in the cardiomyocytes changed from a diffuse pattern toward an alternating pattern demonstrating either low or strong expression of ACT (on-off effect) in different cardiomyocytes, mainly in the central area of the myocardium. In contrast, expression in the endothelium and in the stromal cells became very low (arrowheads; Figure 3B ). In controls ( Figure 3C ), cardiomyocytes stained weak with only very occasionally an on-off effect. Stromal cells and capillaries stained moderately. The unweighted kappas showed excellent agreement in ACT staining of cardiomyocytes, endothelial tissue, and stromal cells (0.90, 0.85, 0.91, respectively). Moreover, the weighted kappas (linear and quadratic) were even higher (0.91 and 0.92 for cardiomyocytes, 0.87 and 0.89 for endothelial tissue, and both 0.91 for stromal cells). 
Figure 2.
Circulating α-1-antichymotrypsin (ACT) protein and ACT mRNA expression. Circulating ACT (μg/mL) in patients with dilated cardiomyopathy (n=18 patients, n=6 controls) before, and 1, 3, and 6 months after continuous-flow-left ventricular assist device (cf-LVAD) implantation, demonstrated in Tukey boxplots (A). After 1 month, there was a nonsignificant increase followed by normalization after 6 months of support. mRNA expression of ACT (B). After cf-LVAD support, there was a significant decrease in mRNA to levels lower than that of controls (n=15 patients, n=9 controls). Some interindividual variation was observed.
To investigate if the on-off effect was caused by induced cell death, we performed double immunohistochemistry staining with anticardiac actin and ACT. Merging the images clearly showed that the contractile elements were present both in the ACT stained and in the nonstained cells ( Figure 4A-4D) , indicating that apoptosis is not related to ACT expression. CG expression was not localized in cardiomyocytes, endothelium, capillaries, or extracellular matrix, but was only present in few scattered mast cells (data not shown).
Post-transcriptional Regulation of ACT by miR-137
According to two major miR target prediction databases, miRanda 13 and Targetscan, 14 ACT is a potential target gene of miR-137. Interestingly, the measuring of miR-137 levels during cf-LVAD support showed that its expression significantly increased in the myocardial tissue (P=0.01; Figure 5 ).
Whereas in pre-LVAD samples, ACT mRNA was present in cardiomyocytes and stromal cells ( Figure 6A ), in post-LVAD samples it could only be detected in cardiomyocytes (partly in the nuclei; Figure 6B ) and no on-off effect was seen. Furthermore, healthy controls ( Figure 6C ) revealed low expression of ACT mRNA and only in the cardiomyocytes (mainly in the nuclei). ACT mRNA was widely expressed in placental positive control tissue ( Figure 6D ). In the parallel experiment demonstrating the specificity of the ACTprobe, interleukin-2 was only expressed in a few interstitial stromal cells ( Figure I in the online-only Data Supplement). Curiously, in pre-LVAD samples ( Figure 7A and 7B) , miR-137 was moderately expressed in cardiomyocytes whereas post-LVAD, miR-137 was expressed in cardiomyocytes and stromal cells ( Figure 7C and 7D) . A scrambled miR was used as a negative control, showing only a weak background staining ( Figure 7E ). U6 was used as a positive control, clearly staining the nuclei as expected ( Figure 7F) .
To address the effect of miR-137 expression on ACT mRNA, we transfected HepG2 cells with miR-137 precursor molecules. Transfection of miR-137 resulted in >50% reduction of ACT mRNA levels ( Figure 8A ), compared with nontransfected cells (P<0.001; mean 45.4±7.6 SEM). As a positive control for transfection, delivery of miR-1 gave rise to significantly lesser mRNA of its validated target protein tyrosine kinase-9 in comparison to the nontransfected cells (P=0.001, Figure 3 . Immunohistochemistry of α-1-antichymotrypsin (ACT) before and after continuous-flow-left ventricular assist device (cf-LVAD) support. Myocardial tissue pre-LVAD (A), post-LVAD (B) support and control (donor hearts declined for heart transplantation; C) was stained. Notice the difference in ACT staining in the cardiomyocytes (diffuse versus on-off effect) and in the stromal cells (pink arrowheads; strong versus no/weak staining) between pre-and post-LVAD tissue. Control tissue showed diffuse cardiomyocyte staining and weak stromal cell staining. with outlier P=0.28; Figure 8B ). Mean mRNA expression of protein tyrosine kinase-9 in the HepG2 cells after transfection of miR-1 was 34.4±9.7 SEM (without outlier) and 63.6±30.3 SEM (with outlier).
To further confirm the functionality of the miR-137 target site in ACT, we cloned the ACT 3′UTR into a luciferase reporter vector. Firefly luciferase was placed under post-translational control of the native 3′UTR of ACT or an ACT 3′UTR harboring a mutated miR-137 target site. Cotransfection of synthetic miR-137 decreased ACT 3′UTR reporter activity (miR-137 versus nontargeting miR, P=0.006; miR-137 versus no miR, P=0.002), whereas no sensitivity was observed after cotransfection of a control, nontargeting miR ( Figure 8C) . In contrast, an ACT 3′UTR reporter with a mutated miR-137 target site showed no sensitivity to miR-137 transfection ( Figure 8D ). Together, these data indicate the presence of a functional miR-137 target site in the 3′UTR of ACT, confirming ACT as a direct target gene of miR-137.
Discussion
In the present study, it is shown that ACT levels decrease both in heart tissue and in plasma samples of cf-LVAD supported HF patients, suggesting a possible role for ACT in reverse remodeling. Immunohistochemically, a homogenous expression pattern of ACT within each individual cardiomyocyte was observed post-LVAD, whereas the expression levels of ACT between cardiomyocytes varied. This alternated expression was not because of apoptosis. The ACT staining in stromal cells in between the cardiomyocytes showed a strong decrease after LVAD support, both at protein (immunohistochemistry) and mRNA (ISH) levels, and could therefore be the main source of the changes observed in plasma ACT during LVAD support. Also, the regulatory function of miRs on ACT was studied. According to miR target prediction databases, only miR-137 was predicted to target ACT. We have shown that by transfecting HepG2 cells with miR-137, mRNA of ACT was decreased >50%, and by using luciferase reporter analysis, including target-site mutagenesis that ACT is a direct target of miR-137. miR-137 was upregulated after cf-LVAD support, which correlates with the reduced mRNA and protein levels of its target ACT. ISH showed that miR-137 expression was mainly localized in the cardiomyocytes as well in stromal cells (post-LVAD), as were ACT mRNA and protein. Of note, ISH is quantitatively not reliable and therefore levels of miR-137 should be interpreted with caution. Unfortunately, it is not possible to analyze the post-transcriptional role of miR-137 on ACT in a murine HF model, because miR-137 will not bind to the UTR of murine ACT mRNA. ISH ACT showed a more homogeneous staining than miR-137 expression, which may imply that regulation of ACT is not strictly regulated, but that regulation of gene transcription is also involved in controlling ACT expression levels.
The role of ACT in HF is unknown. Inflammatory activity is thought to be a key player in the progression of HF. ACT, SERPINA3 (serpin peptidase inhibitor, clade A, member 3), is an acute-phase protein and induces the proinflammatory cytokine tumor necrosis factor-α, and nuclear factor-κB. 15 Interestingly, tumor necrosis factor-α also controls the synthesis of ACT. 16 tumor necrosis factor-α, which is under the control of nuclear factor nuclear factor-κB activation, is produced A and B) , miR-137 expression was weak in cardiomyocytes and almost negative in stromal cells (arrowheads) at ×20 (A) and at ×40 magnification (B). Post-LVAD (C and D), miR-137 staining was positive in stromal cells (arrowheads) and in the cardiomyocytes at ×20 (C) and ×40 magnification (D). No clear on-off effect was observed. In the negative scramble in situ hybridization (E), a weak background staining was observed in the cardiomyocytes (not in the stromal cells). A strong staining of U6 in the nuclei was detected (arrowheads; F). locally in the context of HF and has been shown to induce cardiomyocyte apoptosis 17 as well as hypertrophic growth 18 and cardiac remodeling. The initial increase in circulating ACT, which we have demonstrated in the present study, might be caused by the surgical procedure of the cf-LVAD implantation.
ACT is the major inhibitor of the extracellular serine protease activity of CG. Activated neutrophils, macrophages, and mast cells secrete CG into the extracellular space to modulate the immune response. 19, 20 The physiological balance between CG and ACT is required for the maintenance of the connective tissue integrity of the heart. Imbalance in favor of CG results in degradation of connective tissue proteins in heart tissue 21 with subsequent cardiomyocyte detachment and apoptosis. 22 A second pathway in which CG can contribute to HF is by converting angiotensin I in angiotensin II, thereby activating the transforming growth factor pathway that results in cardiomyocyte necrosis, hypertrophy, and increased fibrosis. 23 Interestingly, ACT expression was present in several microarray analyses of the failing myocardium. [24] [25] [26] [27] These data implicate that ACT limits the proteolytic activity in the human heart by inhibition of CG. LVAD implantation leads to a reversal of HF and accordingly, less inflammation and less mast cells and, thereby, less secretion of CG resulting in less need for ACT. This may explain the decrease in ACT during cf-LVAD support in the present study.
ACT has also been associated with the prevention of skeletal muscle degeneration and injury. Circulating ACT increased early after exercise-induced muscle loss 28 and has been related to the preservation of muscle mass in elderly patients. 29 An increased accumulation of ACT has been demonstrated in muscle fibers of patients with inclusion-body myositis, which is an inflammatory muscle disease characterized by progressive muscle weakness and wasting. 30 ACT is also thought to be protective during ischemia reperfusion by inhibiting neutrophil accumulation into the ischemic-reperfused myocardium and by inactivating cytotoxic metabolites released from neutrophils. 31 Figure 8 . MicroRNA (miR)-transfection and luciferase reporter assay. α-1-antichymotrypsin (ACT) mRNA (A) and protein tyrosine kinase-9 (PTK-9) mRNA (B) were significantly downregulated after miR-137 (n=10 experiments) and miR-1 transfection (n=7 experiments), in comparison with the nontransfected cells (*P<0.05). The nontransfected human hepatoma cell lines were set on 100%. There was one outlier in the miR-1 transfection PTK-9 experiment; data are presented without this outlier. In the luciferase reporter assays (n=4 experiments; C and D), luciferase activity was significantly decreased after miR-137 transfection (*P<0.05), in comparison to the nontargeting miR or without miR (C). The reduction in luciferase activity was completely abrogated after mutating the predicted miR-137 binding site in ACT 3′untranslated region (D). Data are presented in scatter plots as mean and SEM.
Likewise, ACT was elevated during the first days after an acute coronary syndrome, 32, 33 and a persistent postoperative increase was noticed after coronary artery bypass grafting. 34 Apart from this important role of ACT as a modulator between inflammation and progression of HF by extracellular mechanisms, it may also have important intracellular effects. ACT has the unique ability among serpins to bind to DNA, a property that is independent of its serine protease inhibitory activity. 35 In the present study, mRNA and protein expression of ACT suggest that high amounts of ACT are present within myocardial cells (especially cardiomyocytes and stromal cells) of end-stage HF patients. Moreover, the peculiar staining pattern of ACT in cardiomyocytes, which alters during cf-LVAD support, could indicate an intracellular role for ACT. These intracellular aspects of ACT require further investigation to understand its role in HF.
The clinical experience with LVADs has been valuable for the identification of mechanisms of reverse remodeling because myocardial tissue of patients with end-stage HF can be obtained at the time of implantation and at the time of HTx, after a period of unloading. There are, however, some recognized limitations of molecular studies in LVAD patients. Our study size was small, and the clinical presentation and duration of support are uncontrolled variables, creating a heterogeneous patient population. Furthermore, the present study comprised relatively young patients with a nonischemic origin of systolic HF. To generalize our findings, it is important to confirm and extend the results in other HF populations. It remains to be determined whether ACT can also be an aid in clinical decision making in the management of individual patients. In addition, we tried to confirm our data in murine models. However, the ACT target site for miR137 in humans is not present in mice.
In summary, plasma ACT is elevated in end-stage HF patients and normalizes during mechanical support. ACT expression is directly regulated by miR-137. ACT and miR-137 are mainly localized in the stromal cells and cardiomyocytes during LVAD support. To the best of our knowledge, miR-137 has not been implicated in cardiovascular disease and this is the first study to show its expression in the human heart, and the shift in expression pattern after unloading the heart by cf-LVAD. Because the expression of ACT is directly regulated by miR-137, and their expression levels are inversely related in vivo, it is tempting to speculate that miR-137 and ACT can play an important role in the pathophysiology of HF and either one could possibly serve as a therapeutic target.
